Engineered Bacteria of MG1363-pMG36e-GLP-1 Attenuated Obesity-Induced by High Fat Diet in Mice
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
Background: Although gut hormone glucagon-like peptide 1 (GLP-1) has been widely used for treating diabetes, the extremely short half-life greatly limits its application. The purpose of this study is to explore the effects of an engineered bacteria with expression of GLP-1 on obese mice induced by high fat diet (HFD). Methods: The engineered strain of MG1363-pMG36e-GLP-1 (M-GLP-1) was constructed and its anti-obesity effects were evaluated in vivo. The bodyweight, the morphology of adipose and liver tissue, and liver function were examined. Quantitative RT-PCR and Western blot were used to measure the expressions of the genes involved in fatty acid oxidation synthesis. The intestinal microbial diversity was detected with high-throughput sequencing analysis. Results: The engineered bacteria could produce GLP-1. It also significantly decreased the bodyweight and improved the glucose intolerance in the obese mice induced by HFD. Moreover, the strain also reduced the triglyceride (TG) in serum, protected liver, as well as decreased the intracellular TG in liver tissues of the obese mice. Furthermore, our results showed that the expressions of the genes including peroxisome proliferator-activated receptors α (PPARα) and its target genes were enhanced in liver tissues when mice treated with M-GLP-1. Finally, we found that the engineered strain markedly increased intestinal microbial diversity. Conclusion: Our results suggested the genetically engineered bacteria that constitutively secreted GLP-1 could improve obesity and the mechanism may be related to promoting fatty acid oxidation and increasing intestinal microbial diversity of the obese mice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1
Drucker, D. J. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.03.001 · Cited by 2,170 · cited 1×
“Emerging evidences indicated that GLP-1 had efficiently treated type 2 diabetes due to its action for lowering blood glucose (Drucker, 2018).”
BackgroundHuman gut microbes impact host serum metabolome and insulin sensitivity
Pedersen, H. K., Gudmundsdottir, V., Nielsen, H. B., Hyotylainen, T., Nielsen, T., Jensen, B. A. H., Forslund, K., Hildebrand, F., Prifti, E., Falony, G., et al. (2016) · Nature · doi:10.1038/nature18646 · Cited by 2,116 · cited 1×
“…it has been reported that the intestinal microbiota had profound roles in the onset and development of obesity via affecting the host’s nutrients acquisition and energy homeostasis that ultimately influence the storage of lipids in fat cells (Rosenbaum et al., 2015; Dahiya et al., 2017).”
BackgroundPawlak, M., Lefebvre, P., & Staels, B. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2014.10.039 · Cited by 1,578
Gut microbiome and serum metabolome alterations in obesity and after weight-loss intervention
Liu, R., Hong, J., Xu, X., Feng, Q., Zhang, D., Gu, Y., Shi, J., Zhao, S., Liu, W., Wang, X., et al. (2017) · Nature Medicine · doi:10.1038/nm.4358 · Cited by 1,501
Loomba, R., Seguritan, V., Li, W., Long, T., Klitgord, N., Bhatt, A., Dulai, P. S., Caussy, C., Bettencourt, R., Highlander, S. K., et al. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.04.001 · Cited by 1,123
The Cardiovascular Biology of Glucagon-like Peptide-1
Drucker, D. J. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.06.009 · Cited by 665 · cited 1×
“In addition to its role in diabetes, GLP-1 also plays protective roles in cardiovascular diseases through its direct and indirect actions such as reducing inflammation and increasing endothelial function (Drucker, 2016).”
BackgroundIsabella, V. M., Ha, B. N., Castillo, M. J., Lubkowicz, D. J., Rowe, S. E., Millet, Y. A., Anderson, C. L., Li, N., Fisher, A. B., West, K. A., et al. (2018) · Nature Biotechnology · doi:10.1038/nbt.4222 · Cited by 605
Glucagon-like peptide 1 in health and disease
Andersen, A., Lund, A., Knop, F. K., & Vilsbøll, T. (2018) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0016-2 · Cited by 543
The gut microbiota in human energy homeostasis and obesity
Rosenbaum, M., Knight, R., & Leibel, R. L. (2015) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2015.07.002 · Cited by 450 · cited 1×
“The mechanisms mainly may be involved in the following aspects including inflammation, intestinal permeability and short-chain fatty acids, and so on (Singer-Englar et al., 2019).”
BackgroundKurtz, C. B., Millet, Y. A., Puurunen, M. K., Perreault, M., Charbonneau, M. R., Isabella, V. M., Kotula, J. W., Antipov, E., Dagon, Y., Denney, W. S., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aau7975 · Cited by 399
The gut microbiota regulates white adipose tissue inflammation and obesity via a family of microRNAs
Virtue, A. T., McCright, S. J., Wright, J. M., Jimenez, M. T., Mowel, W. K., Kotzin, J. J., Joannas, L., Basavappa, M. G., Spencer, S. P., Clark, M. L., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aav1892 · Cited by 317
Duan, F. F., Liu, J. H., & March, J. C. (2015) · Diabetes · doi:10.2337/db14-0635 · Cited by 263 · cited 1×
“…commensal bacteria which could February 2021 | Volume 11 | Article 595575 express full-length form of GLP-1 (1-37), and they found the strain could be taken orally to improve diabetes because the intestinal cells were reprogrammed as glucose-reactive insulinsecreting cells (Duan et al., 2015).”
BackgroundGlucagon-like peptides 1 and 2 in health and disease: A review
Marathe, C. S., Rayner, C. K., Jones, K. L., & Horowitz, M. (2013) · Peptides · doi:10.1016/j.peptides.2013.01.014 · Cited by 100
Glucagon-like peptide 1 regulates adipogenesis in 3T3-L1 preadipocytes
YANG, J., REN, J., SONG, J., LIU, F., WU, C., WANG, X., GONG, L., LI, W., XIAO, F., YAN, F., et al. (2013) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2013.1350 · Cited by 84
Fang, X., Tian, P., Zhao, X., Jiang, C., & Chen, T. (2019) · Journal of Neurochemistry · doi:10.1111/jnc.14694 · Cited by 72
Self-citationChen, T., Tian, P., Huang, Z., Zhao, X., Wang, H., Xia, C., Wang, L., & Wei, H. (2018) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-018-9155-6 · Cited by 52 · cited 1×
“The fragment was inserted into pMG36e, a prokaryotic expression vector (Chen et al., 2018; Fang et al., 2019) to get the plasmid of pMG36e-GLP-1.”
MethodSelf-citation
Cited by
Role of the gut-brain axis in energy and glucose metabolism
Wachsmuth, H. R., Weninger, S. N., & Duca, F. A. (2022) · Experimental & Molecular Medicine · doi:10.1038/s12276-021-00677-w · Cited by 269
Glucagon-Like Peptide-1: New Regulator in Lipid Metabolism
Bu, T., Sun, Z., Pan, Y., Deng, X., & Yuan, G. (2024) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2023.0277 · Cited by 131
Genetically Engineered Microorganisms and Their Impact on Human Health
Mahdizade Ari, M., Dadgar, L., Elahi, Z., Ghanavati, R., & Taheri, B. (2024) · International Journal of Clinical Practice · doi:10.1155/2024/6638269 · Cited by 67
Yue, M., Wei, J., Chen, W., Hong, D., Chen, T., & Fang, X. (2022) · Nutrients · doi:10.3390/nu14224886 · Cited by 62
Self-citation
Metadata
- Authors
- Wang, L., Chen, T., Wang, H., Wu, X., Cao, Q., Wen, K., Deng, K.-Y., & Xin, H.
- Venue
- Frontiers in Cellular and Infection Microbiology
- Publisher
- Frontiers Media SA
- Published
- 2021-02-25
- Volume
- 11
- Pages
- 595575-595575
- ISSN
- 2235-2988 (ISSN-L)
- OpenAlex
- W3131883888
- Cited by
- 40
- References
- 16
- FWCI
- 1.95
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.